The US plans to slash the price it pays for Novo Nordisk’s Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over ...
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback